Latest Regulatory Clearance News

Fatfish Group Limited has refinanced its $5.67 million debt with Arena Investors LP and secured an additional $0.15 million through new convertible notes, including a board nomination right for Arena.

BlueScope Steel has received a $30 per share takeover proposal from a consortium of SGH Limited and US-based Steel Dynamics, sparking fresh speculation about the steelmaker's future.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

RPMGlobal shareholders convened on 19 December 2025 to vote on Caterpillar's $5.00 per share acquisition proposal, with strong board support and regulatory hurdles nearing resolution.

ASPI Isotopes Inc. and Renergen Limited have received regulatory clearance to proceed with their Scheme of Arrangement, setting a detailed timetable for share suspensions, listings, and settlements complicated by cross-border processes.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Zeus Resources has secured Forestry Department approval to begin trenching at its Casablanca Antimony Project in Morocco, clearing a key regulatory hurdle for exploration. The program aims to refine geological understanding and target high-grade antimony mineralization.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

EV Resources is set to begin a fully funded maiden diamond drilling program at its high-grade Los Lirios antimony project in Mexico, aiming to define a maiden JORC resource by Q3 2026. This marks a pivotal step toward production readiness and a broader 2026 exploration campaign.

Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.

LTR Pharma has received regulatory clearance from the Therapeutic Goods Administration to commence its Phase II clinical trial of SPONTAN, focusing on men aged 65 and over. Patient recruitment is set to begin early next year, aiming to address a key gap in erectile dysfunction treatment.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.